XORTX Therapeutics (TSXV:XRTX) GF Value : C$0.00 (As of Nov. 14, 2024)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics GF Value?

As of today (2024-11-14), XORTX Therapeutics's share price is C$1.94. XORTX Therapeutics's GF Value is C$0.00. Therefore, XORTX Therapeutics's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes XORTX Therapeutics is Not Valued.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

XORTX Therapeutics (TSXV:XRTX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

XORTX Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.94	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XORTX Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Executives

Allen Warren Davidoff	Director, Senior Officer
Amar Deep Keshri	Senior Officer
William Bruce Rowlands	Director
James Neville Fairbairn	Senior Officer
Allan William Williams	Director
Paul Joseph Van Damme	Director